Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)

13 november 2026 bijgewerkt door: Enliven Therapeutics

A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Studie Overzicht

Gedetailleerde beschrijving

This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.

Studietype

Ingrijpend

Inschrijving (Geschat)

450

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Werving
        • Winship Cancer Institute
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46260
        • Werving
        • Investigative Clinical Research of Indiana, LLC
    • New Jersey
      • Morristown, New Jersey, Verenigde Staten, 07960
        • Werving
        • Atlantic Health System
    • Utah
      • Ogden, Utah, Verenigde Staten, 84405
        • Werving
        • Community Center Trials of Utah

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Male or female at least 18 years of age
  • Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
  • Prior treatment with 1 or more BCR::ABL1 TKI(s)
  • Failure or intolerance on the immediate prior TKI
  • Adequate end organ function as measured by blood tests

Exclusion Criteria:

  • Known T315I mutation
  • Known second chronic phase of CML after previous progression to accelerated or blast phase
  • Any serious or uncontrolled medical disorder
  • QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • Previous treatment with a hematopoietic stem-cell transplantation

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: ELVN-001

ELVN-001

ELVN-001 orally daily

Actieve vergelijker: Investigator-selected TKI

Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib

TKI orally daily

Andere namen:
  • Dasatinib
  • Nilotinib
  • Bosutinib

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: 24 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

24 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: 96 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

96 weeks
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability.

planned total follow-up duration of 5 years
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR

planned total follow-up duration of 5 years
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death

planned total follow-up duration of 5 years
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale

planned total follow-up duration of 5 years
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol

planned total follow-up duration of 5 years
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause

planned total follow-up duration of 5 years
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

OS is defined as the time from randomization to death from any cause

planned total follow-up duration of 5 years
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale

planned total follow-up duration of 5 years
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

This is defined as the time from randomization to discontinuation of study treatment due to an adverse event

planned total follow-up duration of 5 years
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Tijdsspanne: planned total follow-up duration of 5 years

Characteristics of AEs will be evaluated to assess safety and tolerability profiles

planned total follow-up duration of 5 years
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Tijdsspanne: planned total follow-up duration of 5 years

Relevant pharmacokinetic parameters will be evaluated

planned total follow-up duration of 5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

31 december 2026

Primaire voltooiing (Geschat)

31 december 2028

Studie voltooiing (Geschat)

1 juli 2033

Studieregistratiedata

Eerst ingediend

23 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

23 oktober 2026

Eerst geplaatst (Werkelijk)

29 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren